Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 8.24
(0.98%)
CNY 8.24
(0.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.66 Billion CNY | 3.89% |
| 2022 | 3.53 Billion CNY | 31.71% |
| 2021 | 2.68 Billion CNY | 5.48% |
| 2020 | 2.54 Billion CNY | 3.48% |
| 2019 | 2.45 Billion CNY | 14.57% |
| 2018 | 2.14 Billion CNY | 87.9% |
| 2017 | 1.14 Billion CNY | 6.98% |
| 2016 | 1.06 Billion CNY | 4.5% |
| 2015 | 1.02 Billion CNY | 42.08% |
| 2014 | 718.34 Million CNY | 15.34% |
| 2013 | 622.78 Million CNY | 27.47% |
| 2012 | 488.56 Million CNY | 15.7% |
| 2011 | 422.26 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 3.2 Billion CNY | -4.57% |
| 2024 Q1 | 3.58 Billion CNY | -2.39% |
| 2024 Q2 | 3.35 Billion CNY | -6.26% |
| 2023 FY | 3.66 Billion CNY | 3.89% |
| 2023 Q2 | 3.7 Billion CNY | -1.03% |
| 2023 Q3 | 3.93 Billion CNY | 6.28% |
| 2023 Q4 | 3.66 Billion CNY | -6.81% |
| 2023 Q1 | 3.74 Billion CNY | 5.99% |
| 2022 Q1 | 2.86 Billion CNY | 7.04% |
| 2022 Q2 | 3.26 Billion CNY | 13.71% |
| 2022 Q4 | 3.53 Billion CNY | 2.29% |
| 2022 Q3 | 3.45 Billion CNY | 5.79% |
| 2022 FY | 3.53 Billion CNY | 31.71% |
| 2021 FY | 2.68 Billion CNY | 5.48% |
| 2021 Q1 | 2.36 Billion CNY | -6.8% |
| 2021 Q2 | 2.33 Billion CNY | -1.24% |
| 2021 Q3 | 2.49 Billion CNY | 6.66% |
| 2021 Q4 | 2.68 Billion CNY | 7.43% |
| 2020 Q1 | 2.48 Billion CNY | 1.33% |
| 2020 FY | 2.54 Billion CNY | 3.48% |
| 2020 Q2 | 2.68 Billion CNY | 7.69% |
| 2020 Q4 | 2.54 Billion CNY | 2.34% |
| 2020 Q3 | 2.48 Billion CNY | -7.33% |
| 2019 Q2 | 2.28 Billion CNY | 0.63% |
| 2019 Q1 | 2.26 Billion CNY | 5.83% |
| 2019 FY | 2.45 Billion CNY | 14.57% |
| 2019 Q4 | 2.45 Billion CNY | 2.69% |
| 2019 Q3 | 2.39 Billion CNY | 4.77% |
| 2018 Q1 | 1.19 Billion CNY | 4.96% |
| 2018 FY | 2.14 Billion CNY | 87.9% |
| 2018 Q4 | 2.14 Billion CNY | 70.55% |
| 2018 Q3 | 1.25 Billion CNY | 7.94% |
| 2018 Q2 | 1.16 Billion CNY | -2.76% |
| 2017 FY | 1.14 Billion CNY | 6.98% |
| 2017 Q1 | 1.09 Billion CNY | 2.9% |
| 2017 Q2 | 1.19 Billion CNY | 9.06% |
| 2017 Q3 | 1.16 Billion CNY | -2.92% |
| 2017 Q4 | 1.14 Billion CNY | -1.81% |
| 2016 Q3 | 1.01 Billion CNY | 0.05% |
| 2016 Q1 | 1.06 Billion CNY | 4.46% |
| 2016 Q2 | 1.01 Billion CNY | -4.55% |
| 2016 Q4 | 1.06 Billion CNY | 4.75% |
| 2016 FY | 1.06 Billion CNY | 4.5% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 FY | 1.02 Billion CNY | 42.08% |
| 2015 Q3 | 961.76 Million CNY | 0.0% |
| 2015 Q4 | 1.02 Billion CNY | 6.12% |
| 2014 Q4 | 718.34 Million CNY | 0.0% |
| 2014 FY | 718.34 Million CNY | 15.34% |
| 2013 FY | 622.78 Million CNY | 27.47% |
| 2012 FY | 488.56 Million CNY | 15.7% |
| 2011 FY | 422.26 Million CNY | 0.0% |